Skip to main content
50°
Sunny
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by C4 Therapeutics, Inc.
C4 Therapeutics to Participate in the Stifel 2024 Targeted Oncology Forum
April 09, 2024
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CCCC
C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024
April 08, 2024
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CCCC
C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC™ Degraders at the American Association for Cancer Research Annual Meeting 2024
March 05, 2024
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CCCC
C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins
March 04, 2024
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CCCC
C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
February 22, 2024
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CCCC
C4 Therapeutics Announces 2024 Priorities and Extended Cash Runway to Advance Portfolio of Targeted Protein Degradation Medicines
January 09, 2024
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CCCC
C4 Therapeutics Announces Closing of $25 Million Equity Investment by Betta Pharmaceuticals
January 04, 2024
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CCCC
C4 Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 04, 2024
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CCCC
C4 Therapeutics Announces Positive Data from CFT7455 Phase 1 Trial in Relapsed/Refractory Multiple Myeloma
December 12, 2023
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CCCC
C4 Therapeutics Announces License and Research Collaboration with Merck to Discover and Develop Degrader-Antibody Conjugates (DACs)
December 12, 2023
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CCCC
C4 Therapeutics to Host Webcast to Present New Dose Escalation Data from CFT7455 Phase 1 Study in Relapsed/Refractory Multiple Myeloma
November 28, 2023
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CCCC
C4 Therapeutics Strengthens Board of Directors with Owen Hughes Appointment
November 20, 2023
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CCCC
C4 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
November 01, 2023
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CCCC
C4 Therapeutics Announces Upcoming Data Presentations for CFT8634, an Orally Bioavailable BiDAC™ Degrader in Development for Synovial Sarcoma and SMARCB1-Null Tumors, and CFT7455, an Orally Bioavailable MonoDAC™ Degrader in Development for Multiple
October 11, 2023
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CCCC
C4 Therapeutics Announces Chief Financial Officer Succession
September 05, 2023
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CCCC
C4 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
August 08, 2023
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CCCC
C4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 17, 2023
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CCCC
C4 Therapeutics Announces FDA Clearance of Investigational New Drug Application for CFT8919, an Orally Bioavailable BiDAC™ Degrader Targeting EGFR L858R for Non-Small Cell Lung Cancer
July 05, 2023
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CCCC
C4 Therapeutics Appoints Leonard Reyno, M.D., as Chief Medical Officer
June 20, 2023
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CCCC
C4 Therapeutics and Betta Pharmaceuticals Announce Exclusive Licensing Agreement for the Development and Commercialization in Greater China of CFT8919, an Orally Bioavailable BiDAC™ Degrader of EGFR L858R for NSCLC
May 30, 2023
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CCCC
C4 Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights
May 04, 2023
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CCCC
C4 Therapeutics to Participate in the Stifel 2023 Virtual Targeted Oncology Days
April 19, 2023
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CCCC
C4 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights
February 23, 2023
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CCCC
C4 Therapeutics to Present at Two Virtual February 2023 Conferences
February 08, 2023
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CCCC
C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT1946, an Orally Bioavailable BiDAC™ Degrader, in BRAF V600 Mutant Solid Tumors
January 30, 2023
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CCCC
C4 Therapeutics Announces 2023 Strategic Priorities to Advance Portfolio of Targeted Protein Degradation Medicines
January 09, 2023
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CCCC
C4 Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 03, 2023
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CCCC
C4 Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights
November 03, 2022
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CCCC
C4 Therapeutics Receives Study May Proceed Letter from U.S. FDA to Initiate Phase 1/2 Clinical Trial of CFT1946, an Orally Bioavailable BiDAC™ Degrader, in BRAF-V600 Mutant Solid Cancers
September 29, 2022
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CCCC
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.